ImmunoPrecise Antibodies (NASDAQ:IPA – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They presently have a $9.00 price target on the stock. HC Wainwright also issued estimates for ImmunoPrecise Antibodies’ Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at ($0.02) EPS, FY2027 earnings at ($0.01) EPS, FY2028 earnings at $0.14 EPS and FY2029 earnings at $0.32 EPS.
Separately, Benchmark reduced their price objective on ImmunoPrecise Antibodies from $5.00 to $3.00 and set a “speculative buy” rating on the stock in a research report on Wednesday, August 14th.
Get Our Latest Analysis on ImmunoPrecise Antibodies
ImmunoPrecise Antibodies Trading Up 14.0 %
ImmunoPrecise Antibodies (NASDAQ:IPA – Get Free Report) last posted its earnings results on Monday, July 29th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.42). The company had revenue of $4.76 million during the quarter, compared to the consensus estimate of $4.92 million. ImmunoPrecise Antibodies had a negative return on equity of 57.05% and a negative net margin of 110.66%. Equities analysts anticipate that ImmunoPrecise Antibodies will post -0.25 EPS for the current fiscal year.
Hedge Funds Weigh In On ImmunoPrecise Antibodies
An institutional investor recently raised its position in ImmunoPrecise Antibodies stock. Renaissance Technologies LLC raised its position in shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA – Free Report) by 70.0% in the second quarter, according to its most recent filing with the SEC. The firm owned 63,910 shares of the company’s stock after purchasing an additional 26,310 shares during the quarter. Renaissance Technologies LLC owned approximately 0.24% of ImmunoPrecise Antibodies worth $65,000 at the end of the most recent quarter. 6.70% of the stock is currently owned by institutional investors and hedge funds.
About ImmunoPrecise Antibodies
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.
Featured Stories
- Five stocks we like better than ImmunoPrecise Antibodies
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- How Much Can You Make in Stocks in One Month?
- Why Invest in 5G? How to Invest in 5G Stocks
- This Is the Top Large-Cap Stock Insiders Are Buying
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for ImmunoPrecise Antibodies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoPrecise Antibodies and related companies with MarketBeat.com's FREE daily email newsletter.